Navigation Links
Proteothera, Inc. Announces Scientific Advisors to Aid in Development of Novel Therapy for Acute Gout Attacks
Date:11/8/2015

ProteoThera, Inc., an early stage biotech platform company that is developing therapies for the local delivery of validated and FDA approved drugs, peptides, and small molecules to treat autoinflammatory diseases and tissue regeneration, today announced the team of scientific advisors who will guide the Company with their development of local delivery of a modified IL-1RA for the relief of pain for patients suffering from acute gout attacks.

“I believe that ProteoThera may be changing the paradigm for the traditional treatment of acute gout flares by potentially offering a safe and effective treatment for acute gout with an early onset of pain relief,” said Dr. Lee Simon, who serves as the Company’s acting Medical Director and lead scientific advisor. “The compilation of these renowned gout experts to serve as advisors for the acute gout therapy development program is a great step towards that goal.”

Advisors to ProteoThera’s acute gout therapy development program include the following experts:

  •     Lee Simon, M.D., Principal, SDG LLC, Former FDA Division Director, Division of Pulmonary, Allergy and Rheumatology Products
  •     Robert Terkeltaub, M.D., Professor of Medicine, University of California, San Diego
  •     Naomi Schlesinger, M.D., Professor of Medicine, Chief of Rheumatology, Rutgers University
  •     Joseph Flood, M.D., Columbus Arthritis Center

“We warmly welcome our new scientific advisors to the ProteoThera team,” said Patrick O’Donnell, President and Chief Executive Officer of ProteoThera. “I am confident that under guidance from this group of leaders in rheumatology with such varied foundations of expertise, our company will make great strides in furthering the development of our lead therapy and further prove out the significant value of our matrix-binding peptide technology platform for the local delivery of numerous commercially validated therapeutics.”

About ProteoThera, Inc.
ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology. The Company's transformative platform technology, a proprietary tissue matrix-binding (MB) peptide technology, is being developed to improve clinical efficacy and safety of FDA approved and validated therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

The MB targeting technology was developed at Brigham and Women’s Hospital and Harvard Medical School. The MB technology can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally or subcutaneous delivered proteins, peptides, and small molecules. ProteoThera’s focus on previously validated or approved therapies greatly de-risks the clinical, regulatory, and commercial pathways. By keeping therapies where they are needed to enable therapeutic effect, the MB platform may also improve the safety profile by reducing or eliminating side effects associated with whole-body systemic exposure.

ProteoThera’s first development priority is the use of PRT-1000 (MB - Interleukin 1 Receptor Antagonist (MB-IL1RA) for treatment of acute gout pain. IL1RA is a potent cytokine inhibitor, already FDA approved for systemic administration in rheumatoid arthritis. Gout is a large and growing market with total gout drug sales projected to double to more than $2 Billion by 2018 in the US and Europe.
###

Read the full story at http://www.prweb.com/releases/2015/11/prweb13068177.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related medicine news :

1. Pixel Film Studios announces the release of FCPX Toolbox Volume 4 which includes Essential Editing Tools for Final Cut Pro X Users.
2. First Choice Emergency Room Announces Dr. Andrew P. Kretschmer as Medical Director of Spring, Texas Facility
3. National Hot Dog and Sausage Council Announces Official Policy On ‘Hot Dog as Sandwich’ Controversy
4. Imagequantify.Com Announces New Iqbot For Quantitative Analysis Of Histological Imaging Data: Dab Stain Analysis
5. The National Center for Homeopathy Announces Constantine Hering, MD Dedication Ceremony
6. IRIS Announces Start of 2nd Annual 30/30 Retinal Screenings Campaign
7. RJ Young Announces Key Leadership Promotions & Additions
8. MTI-GlobalStem Announces Collaboration for First Commercial In Vitro Test System for Human Neuroprotection in Proteopathic Diseases, Such As Alzheimer’s and Parkinson’s
9. Dr. Michael Feiz Announces a Successful Outcome for Needlescopic Surgery Streamed Live at the 2015 ASMBS Conference
10. Career Training Academy Announces Relocation, Expansion for New Kensington Campus
11. Above and Beyond Family Center Announces Premier Public Reception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... CO (PRWEB) , ... April 25, 2017 , ... ... and Liberty attempts to compare student test score performance for the 2015-16 school ... of the state’s voucher programs. Though it highlights important patterns in student test ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology: